- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05059379
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer (SUCLANODE)
A Multicenter Randomized Controlled Phase III Study of Medial vs. Entire Supraclavicualr Lymph Node Radiation Therapy for Patients With Pathologically Positive Axillary Lymph Node and High Risk of Recurrence After Breast Cancer Surgery
Study Overview
Status
Detailed Description
PRIMARY OBJIECTIVE:
I. To evaluate whether entire supraclavicular lymph node irradiation is superior to medial supraclavicular lymph node irradiation in terms of disease free survival for patients with positive lymph nodes and high risk of recurrence after breast cancer surgery
SECONDARY OBJECTIVES:
I. To estimate the difference of overall survival II. to estimate the difference of ipsilateral supraclavicular node recurrence III. to estimate the difference of local regional recurrence IV. to estimate the difference of radiation related toxicities and quality of life.
Outline: Beginning 2-12 weeks after the completion of breast cancer surgery and neoadjuvant/adjuvant chemotherapy, patients are randomized to 1 of 2 treatment arms Arm I: Patients undergo breast/chest wall, undissected axillary, internal mammary node and medial supraclavicular node radiation. Conventional fractionated radiotherapy 50Gy/25Fx/5w or hypofractionated 42.5Gy/16Fx/3.5week with IMRT or VAMT technique is recommended. 3DCRT technique is not permitted.
Arm II: Patients undergo breast/chest wall, undissected axillary, internal mammary node and entire supraclavicular node radiation. Conventional fractionated radiotherapy 50Gy/25Fx/5w or hypofractionated 42.5Gy/16Fx/3.5week with IMRT or VAMT technique is recommended. 3DCRT technique is not permitted
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Zhaozhi Yang, M.D.
- Phone Number: 86 18017317126
- Email: yzzhi2014@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhaozhi C Yang
- Phone Number: +8618017317126
- Email: yzzhi2014@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ECOG 0-1
- Newly diagnosed invasive breast cancer
- Initial clincial diagonosis stage is T1-4, N0-3a/b, M0: If neoadjuvant chemotherapy was not administered: pathological stage is T1-3N2-3a/b, M0; If neoadjuvant chemotherapy was administered:clinical stage III or pathological stage is T1-4N1-3a/bM0.
- Underwent breast conservative surgery or Mastectomy with or without breast reconstruction with clear negative margin. At least, axillary level I and level II should be cleared with ≥10 lymph node (including the number of sentinal lymph node) . Level III dissection and internal mamamry node dissection are not required, but may be performed at the discretion of the surgeon.
- Should receive ≥6 cycles standard neoadjuvant and/or adjuvant chemotherapy (taxane and/or anthracycline based).
- Enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy.
- For ER and/or PR positive patients, the duration of anticipated endocrine therapy should be≥5 year ; For HER2 postive patients, the duration of anticipated herceptin should be 1 year.
- Writtern, informed consent.
Exclusion Criteria:
- Initinal clinical diagnosis N3c (supraclavicualr node metastasis)
- T4 or inflamed breast cancer with no good downstage by neoadjuvant chemotherapy
- Distant metastasis
- Bilateral breast cancer or previously contralateral breast cancer
- Positve sentinal lymph node with no axillary dissection
- ECOG ≥2
- Could not tolerate chemotherapy and anti-HER2 target treatment
- Active infectious
- History of radiotherapy
- Serious medical complcation
- Breast cancer during pregnancy and lactation
- Had simultaneousl or previous secondary malignancies, except for skin basal cell carcinoma and cervical carcinoma in situ.
Inaccessibility for follow-up
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Breast/chest wall+undisseted axillary+IMN+medial SCL ( medial SCL radiation)
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and medial supraclavicular node.
Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w).
IMRT and VMAT technique are recommended.
|
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
|
Experimental: Breast/chest wall+undisseted axillary+IMN+entie SCL (entire SCL radiation)
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular node.
Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w).
IMRT and VMAT technique are recommended.
|
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival (DFS )
Time Frame: Up to 5 years after completion of radiation therapy
|
defined as time from randomization until to local, regional, or distant recurrence, or any death, or secondary primary cancer
|
Up to 5 years after completion of radiation therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to 5 years after completion of radiation therapy
|
defined as time from any death
|
Up to 5 years after completion of radiation therapy
|
Ipsilateral supraclavicular lymph node recurrence (ISLNR) )
Time Frame: Up to 5 years after completion of radiation therapy
|
defined as entire ipsilateral supraclavicular lymph node recurrence
|
Up to 5 years after completion of radiation therapy
|
Local reigonal recurrence (LRR)
Time Frame: Up to 5 years after completion of radiation therapy
|
chest wall, breast , regional lymph node recurrence
|
Up to 5 years after completion of radiation therapy
|
Distance metastasis (DS)
Time Frame: Up to 5 years after completion of radiation therapy
|
any recurrence in all areas beyond local, regional and death due to breast cancer
|
Up to 5 years after completion of radiation therapy
|
incidence of adverse events
Time Frame: Up to 5 years after completion of radiation therapy
|
Adverse events categorized using the NCI Common Terminology for Adverse Events Version 4.0 (CTCAE v4.0)
|
Up to 5 years after completion of radiation therapy
|
difference of quality of life
Time Frame: Up to 5 years after completion of radiation therapy
|
evaluate the quality of life according to EROTC-QLQ-C30 and QLQ BR23
|
Up to 5 years after completion of radiation therapy
|
differences in upper limb function
Time Frame: Up to 5 years after completion of radiation therapy
|
evaluate the upper limb function by Quick-dash
|
Up to 5 years after completion of radiation therapy
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Zhaozhi Yang, M.D, Fudan University
- Study Chair: Xiaomao Guo, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDRT-BC017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Medial supraclavicular lymph node radiotherapy
-
Xinhong Wu, PhDCompletedBreast Cancer Stage IIIChina
-
Sun Yat-sen UniversityNot yet recruitingBreast Cancer | Ipsilateral Supraclavicular Lymph Node Metastasis
-
University of MinnesotaWithdrawn
-
Samsung Medical CenterRecruitingBreast Cancer Stage IIIKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...RecruitingBreast Cancer | Pathological Complete Response | Axillary Lymph Node Dissection | Neoadjuvant Systemic Therapy | Axillary LymphChina
-
Ruijin HospitalRecruiting
-
University Hospitals of Derby and Burton NHS Foundation...RecruitingBreast Cancer | Sentinel Lymph Node | Neoplasm, BreastUnited Kingdom
-
University Hospital A CoruñaComplejo Hospitalario Universitario de Vigo; Complejo Hospitalario Universitario... and other collaboratorsRecruiting
-
Duke UniversityCompletedProstate CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIC Skin Melanoma | Stage IV MelanomaUnited States